Pfizer Prevnar vaccine wins expanded approval, for ages 6-17
Jan 25 (Reuters) - Pfizer Inc on Friday said U.S. regulators had approved wider use of its Prevnar 13 vaccine to prevent infections with pneumococcal bacteria, for children and adolescents aged 6 years to 17 years.
The product, one of Pfizer's biggest brands, was approved in the United States in early 2010 to prevent infections among infants and young children. The bacteria can cause pneumonia, ear infections and other problems.
- Tesla says in talks with BMW over car batteries, parts
- Exclusive: China ready to cut rates again on fears of deflation - sources
- Actor Dwight Henry eyed in New Orleans killing after arrest for theft
- China building South China Sea island big enough for airstrip: report
- Obama to Republican critics on immigration: 'Pass a bill'
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video